Exact Sciences Corporation (NASDAQ:EXAS)‘s stock had its “buy” rating reaffirmed by equities research analysts at Robert W. Baird in a research note issued to investors on Friday. They currently have a $49.00 target price on the medical research company’s stock. Robert W. Baird’s price objective would suggest a potential upside of 0.78% from the company’s previous close.

A number of other analysts also recently commented on EXAS. Canaccord Genuity lowered their target price on Exact Sciences Corporation from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, June 9th. Bank of America Corporation restated a “buy” rating and issued a $38.00 target price (up previously from $34.00) on shares of Exact Sciences Corporation in a research note on Monday, June 12th. Vetr upgraded Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating and set a $36.39 target price on the stock in a research note on Tuesday, June 13th. BidaskClub downgraded Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 16th. Finally, Craig Hallum upped their target price on Exact Sciences Corporation from $35.00 to $41.00 in a research note on Friday, July 7th. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $43.71.

Exact Sciences Corporation (NASDAQ EXAS) opened at 48.63 on Friday. The stock’s 50 day moving average price is $43.40 and its 200-day moving average price is $35.15. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $50.65. The stock’s market capitalization is $5.79 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The firm had revenue of $57.65 million for the quarter, compared to the consensus estimate of $47.73 million. On average, equities analysts expect that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

WARNING: “Exact Sciences Corporation (EXAS) Rating Reiterated by Robert W. Baird” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.watchlistnews.com/exact-sciences-corporation-exas-rating-reiterated-by-robert-w-baird/1616608.html.

In other news, Director Thomas D. Carey bought 2,500 shares of the firm’s stock in a transaction dated Thursday, August 17th. The shares were acquired at an average price of $37.71 per share, for a total transaction of $94,275.00. Following the completion of the transaction, the director now directly owns 60,858 shares in the company, valued at approximately $2,294,955.18. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP D Scott Coward sold 29,115 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the transaction, the senior vice president now owns 64,991 shares in the company, valued at approximately $3,064,975.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 237,444 shares of company stock worth $10,412,421. Company insiders own 4.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. purchased a new position in shares of Exact Sciences Corporation in the second quarter valued at approximately $106,000. Krilogy Financial LLC lifted its position in shares of Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 3,650 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares in the last quarter. Financial Architects Inc lifted its position in shares of Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after acquiring an additional 2,035 shares in the last quarter. Finally, Johnson Financial Group Inc. lifted its position in shares of Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 85.23% of the company’s stock.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.